In Africa, genitourinary and sex hormone testing has increased by 267% over the last decade, the largest increase in any part of the world.
The region ranks first in the growth rate of current trials compared to the sixth ranking in 2010.
These numbers come from GlobalData’s extensive clinical trial database and seek to track the number of clinical trials being conducted in countries around the world and in numerous therapeutic areas.
In Africa, genitourinary and sex hormone-related trials have increased significantly.
Between 2010 and 2020, the number of trials conducted increased by 267%.
In 2020, the largest percentage of trials in the region were conducted in Egypt, and 90.9% of all trials conducted in the region were conducted in Egypt.
In South Africa and Zambia, the proportion of trials conducted in this region was the second highest, at 9.1% and 0%, respectively.
In the Middle East, genitourinary and sex hormone testing increased by 100%.
In Iran, the most trials were conducted in 2020, at 77.6%.
Trials in Israel and Jordan also accounted for the majority of the trials that took place, at 12.1% and 5.2%, respectively.
In the Asia Pacific region, the number of trials conducted increased by 72%.
China, India and Japan conducted the most tests in the region, with 47.7%, 16.6% and 6.8%, respectively.
In Europe, genitourinary and sex hormone-related trials were reduced by 3%.
In the UK, the percentage of trials held in the region was the highest at 9%.
Russia and Germany also accounted for a significant proportion of the trials being held.
In North America, the number of genitourinary and sex hormone tests has decreased.
In this area, the number of trials has decreased by 18%.
The United States accounts for 82.4%, the largest percentage of trials conducted in the region.
Canada and Mexico also accounted for the majority of the trials conducted at 16% and 1.7%, respectively.
South and Central America
In South and Central America, genitourinary and sex hormone tests showed the largest reductions.
The number of trials in the region decreased by 19% between 2010 and 2020.
In Brazil, the percentage of trials conducted in this region was the highest at 40.9%.
https://www.pharmaceutical-technology.com/features/africa-has-seen-the-largest-growth-in-genito-urinary-system-and-sex-hormones-related-trials-over-the-past-decade/ Africa has seen the largest growth in genitourinary and sex hormone-related trials over the last decade.